About ABIVAX Societe Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops, markets, and commercializes treatments for the treatment of autoimmune diseases, viral infections, and cancer in France. Its principal products include ABX 464 that is in Phase IIb clinical trials for the treatment of anti-inflammatory and ulcerative colitis; and Phase IIa clinical trial for the treatment of Crohn's and rheumatoid arthritis diseases, as well as has completed Phase IIa clinical trial for the treatment of viral disease in patients with HIV. It also develops ABX 196, an art immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company's pre-clinical programs ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier 2 Science and Technology, and the Curie Institute. The company was incorporated in 2013 and is headquartered in Paris, France.